These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35968335)

  • 1. Short chain fatty acids exhibit selective estrogen receptor downregulator (SERD) activity in breast cancer.
    Schoeller A; Karki K; Jayaraman A; Chapkin RS; Safe S
    Am J Cancer Res; 2022; 12(7):3422-3436. PubMed ID: 35968335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
    Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
    Front Chem; 2019; 7():602. PubMed ID: 31552220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
    Zhou F; Yang G; Xue L; Liu Y; Guo Y; Zhu J; Yuan L; Gu P; Tang F; Shan J; Tang R
    Breast Cancer Res; 2023 Aug; 25(1):96. PubMed ID: 37580832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
    Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
    de Cremoux P; Dalvai M; N'Doye O; Moutahir F; Rolland G; Chouchane-Mlik O; Assayag F; Lehmann-Che J; Kraus-Berthie L; Nicolas A; Lockhart BP; Marangoni E; de Thé H; Depil S; Bystricky K; Decaudin D
    Breast Cancer Res Treat; 2015 Jan; 149(1):81-9. PubMed ID: 25503779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
    Shomali M; Cheng J; Sun F; Koundinya M; Guo Z; Hebert AT; McManus J; Levit MN; Hoffmann D; Courjaud A; Arrebola R; Cao H; Pollard J; Lee JS; Besret L; Caron A; Bangari DS; Abecassis PY; Schio L; El-Ahmad Y; Halley F; Tabart M; Certal V; Thompson F; McCort G; Filoche-Rommé B; Cheng H; Garcia-Echeverria C; Debussche L; Bouaboula M
    Mol Cancer Ther; 2021 Feb; 20(2):250-262. PubMed ID: 33310762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
    Wardell SE; Marks JR; McDonnell DP
    Biochem Pharmacol; 2011 Jul; 82(2):122-30. PubMed ID: 21501600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
    Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
    Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
    Fanning SW; Jeselsohn R; Dharmarajan V; Mayne CG; Karimi M; Buchwalter G; Houtman R; Toy W; Fowler CE; Han R; Lainé M; Carlson KE; Martin TA; Nowak J; Nwachukwu JC; Hosfield DJ; Chandarlapaty S; Tajkhorshid E; Nettles KW; Griffin PR; Shen Y; Katzenellenbogen JA; Brown M; Greene GL
    Elife; 2018 Nov; 7():. PubMed ID: 30489256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.
    Guo S; Zhang C; Bratton M; Mottamal M; Liu J; Ma P; Zheng S; Zhong Q; Yang L; Wiese TE; Wu Y; Ellis MJ; Matossian M; Burow ME; Miele L; Houtman R; Wang G
    Oncotarget; 2018 Jan; 9(6):6924-6937. PubMed ID: 29467940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
    Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
    Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.